Introduction
In many species, melatonin is a chronobiotic (Redman, 1997) . In humans, melatonin administration phase shifts and/or stabilizes circadian rhythms (reviews: Lewy and Sack, 1997; Arendt et al., 1999) . A phase-response-curve (PRC) to melatonin based on administration for four consecutive days showed approximately opposite timing to the PRC to light (Lewy et al., 1992 (Lewy et al., , 1998 Lewy and Sack, 1997) . A somewhat dierent timing was found after a single infusion of melatonin, both advances and delays occurring later (Zaidan et al., 1994) .
A`classic' PRC measures phase shifts following a single exposure to a zeitgeber under free-running conditions. In humans, this has been performed for the PRC to light (Honma et al., 1987; Minors et al., 1991) but is obviously a dicult undertaking. An acceptable variant is to measure entrained phase position under the controlled unmasking conditions of a constant routine (CR) protocol before and after zeitgeber administration (e.g. a single light pulse, Dawson et al., 1993; Jewett et al., 1994; KraÈ uchi et al., 1997c) . In particular, the measurement of multiple circadian rhythms that shift in parallel (such as core body temperature and melatonin) provides convincing evidence that indeed a phase shift in the circadian pacemaker has been achieved.
There is good consensus that a single application of melatonin in the early to late evening can induce a phase advance of about 1 hr, with some dose dependency (e.g. Deacon and Arendt, 1995; KraÈ uchi et al., 1997a; Wirz-Justice et al., 1999) . However, few studies have investigated the putative phase delay after a single application of melatonin in the early morning, and the most controlled study has been equivocal . The present design completed a series of identical protocols investigating the phase shifting potential of a single administration of 5 mg melatonin on multiple circadian markers, and focused on the most probable timing for a delay at 07:00 hr Lewy et al., 1998) .
Methods

Study design
The experiment lasted 22 days. Subjects remained under normal ambulatory conditions and were required to keep their habitual bedtime constant for the entire duration of the study except for two blocks of three nights and 2 days in the laboratory. Here they remained supine under a modi®ed CR protocol for 58 hr (Fig. 1) . Day 1 was used to measure acute eects (KraÈ uchi et al., 2000; Werth et al., Wirz-Justice A, Werth E, Renz C, MuÈ ller S, KraÈ uchi K. No evidence for a phase delay in human circadian rhythms after a single morning melatonin administration. J. Pineal Res. 2002; 32: 1±5. ã Munksgaard, 2002 Abstract: Although there is good consensus that a single administration of melatonin in the early evening can phase advance human circadian rhythms, the evidence for phase delay shifts to a single melatonin stimulus given in the early morning is sparse. We therefore carried out a double-blind randomizedorder placebo-controlled study under modi®ed constant routine (CR) conditions (58 hr bedrest under 8 lux with sleep 23:00±07:00 hr) in nine healthy young men. A single (pharmacological) dose of melatonin (5 mg p.o.) or a placebo was administered at 07:00 hr on the ®rst morning. Core body temperature (CBT) and heart rate (HR) were continuously recorded, and saliva was collected half-hourly for assay of melatonin. Neither the timing of the mid-range crossing times of temperature (MRCT) and HR rhythms, nor dim light melatonin onset (DLMOn) or oset (DLMO) were phase shifted the day after melatonin administration compared with placebo. The only change was an altered wave form of the CBT rhythm: longer duration of higher-than-average temperature after melatonin administration. Under the same modi®ed CR conditions we have previously demonstrated a clear phase advance of the above circadian rhythms following a single administration of 5 mg melatonin in the evening. This study's failure to ®nd signi®cant delays to a single administration does not negate other positive ®ndings with multiple doses, which may be necessary for a`weak zeitgeber'.
2000; Graw et al., 2001) , day 2 (presented here) to measure eects on circadian phase position. The design was a placebo controlled, double-blind crossover administration of melatonin (5 mg p.o.) or placebo at 07:00 hr, with placebo also given at 07:00 hr on the second day.
Subjects
Nine male volunteers [aged 23.6 2.8 yr (S.D.); body mass index (BMI) 22.5 2.2] completed both blocks of the study between November 1998 and August 1999 after an adaptation night in the laboratory. All subjects were nonsmokers, free of medication and underwent a medical examination prior to study. Neither shift work nor transmeridian travel (>2 time zones) in the month before the study was allowed. Subjects were requested to refrain from alcohol and excessive exercise, and to consume no caeine products after noon for 3 days before the experiment until 3 days after it was ®nished. The protocol was approved by the ethical committee of the University of Basel Medical School and subjects gave written informed consent. No deleterious side-eects were registered. Fig. 1 
Variables (timing intervals detailed in
)
Actimetry documented the subjects' rest-activity cycle and thus compliance with the protocol. They wore a small, non-invasive activity monitor (Actiwatch Ò Cambridge Neurotechnology, Cambridge, UK) on the non-dominant wrist day and night throughout the entire experimental period (data not shown).
Body and skin temperatures were recorded on a Therm-5000-2 unit. Core body temperature (CBT, probe inserted 10 cm into the rectum) was continuously measured in 2-min-intervals (later collapsed in 30-min bins). The ®rst 2 hr were excluded from the analysis because of postural eects after lying down (KraÈ uchi et al., 1997b) . Thereafter, each curve was smoothed by 1-hr moving averages.
Standard electrocardiogram leads continuously recorded heart rate (HR; later collapsed in 30-min bins). After excluding the ®rst 2 hr, each curve was smoothed by 2-hr moving averages.
Saliva was collected at 30-min intervals during waking. Samples were assayed for melatonin using a highly speci®c direct double-antibody RIA, validated by gas chromatography±mass spectrometry (GCMS), with an analytical least detectable dose of 0.15 pg/mL and a functional least detectable dose of 0.65 pg/mL (BuÈ hlmann Laboratories, Switzerland; Weber et al., 1997) .
The mid-range crossing times (MRCT) of the evening decline and morning rise in CBT and HR were used as circadian phase markers and calculated as detailed in KraÈ uchi et al. (1997a) . For each subject, the minimum value (in°C and beats/min) and the maximum value (in°C and beats/min) of the 24-hr curve were averaged ( midrange value, in°C and beats/min).This value was taken to determine the MRCT for each subject, and averaged across subjects. The CBT and HR minima could not be used as a phase marker due to masking by sleep. Dim light melatonin onset (DLMOn), previously validated under identical conditions (KraÈ uchi et al., 1997a) , was used as a sensitive marker for circadian phase. Morning melatonin oset (DLMO) was also calculated, but it is a somewhat more problematic circadian phase marker (see Lewy et al., 1999) . For each subject, the DLMOn and DLMO was determined by linear interpolation as the time when melatonin levels crossed a 3-pg/mL threshold.
Statistics
Dierences between the melatonin and placebo condition were analysed by two-way analyses of variance for repeated measures (rANOVA) with the repeated factor time and Fig. 1 . Protocol of the modi®ed constant routine (CR) protocol lasting 58 hr. Subjects entered the lab in the evening and were allowed three consecutive nights of sleep, with 2 days under supine constant routine (CR) conditions (no change in posture throughout). Melatonin (5 mg p.o.) or placebo was given at 07:00 hr on day 1, and a placebo given at 07:00 hr on day 2. Saliva was collected half-hourly for assay of melatonin; core body temperature (CBT) and skin temperatures and heart rate (HR) were measured continuously throughout. The data from day 1 were used to estimate acute eects (not shown here), data from day 2 for the eects on circadian phase. the nominal factor group (placebo versus melatonin). All P-values derived from rANOVA were based on Huynh± Feldt's corrected degrees of freedom, but the original degrees of freedom are reported. Duncan's multiple range test was used for post hoc comparisons. Only signi®cant results (P < 0.05) are presented.
Results
Exogenous administration of 5 mg melatonin showed classic pharmacokinetics, with a rapid peak attaining 4199 1377 (S.D.) pg/mL 30 min after melatonin intake and a biological half-life of 49 6 min.
The mean raw data for each variable are presented across the last 32 hr of the 58-hr study, i.e. beginning 16 hr after morning melatonin intake (Fig. 2) . In none of the measured circadian rhythms was a statistical dierence between placebo and melatonin found. The apparent delay in CBT and HR minima during sleep was non-signi®cant.
None of the circadian phase markers extracted from the CBT, HR, and salivary melatonin rhythms were shifted after morning melatonin administration (Fig. 3) . The only signi®cant dierence was a longer duration of the circadian peak of CBT.
Discussion
A single administration of 5 mg melatonin at 07:00 hr did not induce the predicted phase delay in any circadian rhythm measured under controlled CR conditions. The caveat required of a negative ®nding is that only one time point and one dose was tested.
Entrainment to a zeitgeber cycle is theoretically not possible if the phase shift to a single pulse is not of sucient magnitude. Our failure to demonstrate a phase delay may indicate that the delay region of a melatonin PRC is less important. As humans have a free-running period >24 hr, it is the phase advancing action of evening melatonin that is relevant for mediating entrainment. Although in some species only phase advances to melatonin within a narrow temporal window are found (Redman, 1997) , this is not true for all species (e.g. Underwood, 1986; Rajaratnam and Redman, 1997; Sharma et al., 1999) .
In contrast to the lack of eect on circadian phase, melatonin administration had immediate neurobiological eects lasting 4±6 hr: psychomotor vigilance was signi®-cantly impaired (Graw et al., 2001) , daytime sleepiness augmented and theta power in the waking EEG increased . Our similarly designed CR studies of 5 mg melatonin given later in the day (at 13:00, 18:00 or 20:40 hr) have all increased sleepiness and theta power in the waking EEG (Cajochen et al., 1997) .
In the protocol most similar to ours, of a single application (albeit infused), no delay occurred when melatonin was given between 04:00 and 07:00 hr, but a delay was induced when melatonin was given between 12:00 and 15:00 hr (Zaidan et al., 1994) . This study was carried out under 150 lux conditions, which now is known to be too high an intensity to provide unmasked melatonin onset times. The authors do note`we suggest that it is easier to advance than to delay phase with melatonin'. The possible weak zeitgeber characteristic of melatonin has been commented on by Lewy:`The phase advance after 1 or 2 days of 0.3 mg melatonin administration was less than after 4 days' (personal communication 7.7. 2000 ). An early study had shown that a single 0.5 mg dose could not advance circadian rhythms, whereas 7 days administration did so (Attenburrow et al., 1995) . The most convincing demonstration of entrainment both by delays and advances has been shown in free-running subjects after repeated melatonin administration . If melatonin is a weak zeitgeber, then a paradigm of successive daily doses may be Fig. 2 . Means (n 9) of core body temperature (CBT) and heart rate (HR) (1-hr moving average), melatonin (30-min intervals beginning on night 2 (16 hr after melatonin or placebo administration) through night 3. As subjects remained supine throughout, there were no postural masking eects on CBT and HR after lights out; however, sleep between 23:00 and 07:00 hr did mask timing of the minima. The small peak after administration of placebo pill at 07:00 hr (to both groups) has been previously observed in our studies.
better suited to reveal the characteristics of a melatonin PRC.
We chose this dose, because many studies, including our own previous CR investigations, have documented an unequivocal phase advance following a single 5 mg intake of melatonin. Also, a dose±response study found greater phase advances after 5 mg than after 0.5 mg (Deacon and Arendt, 1995) . It has been argued that such high doses are not`physiological' and thus invalid. Yet levels of melatonin in the CSF are much higher than in the blood (Shaw et al., 1989; Skinner and Malpaux, 1999) , and it is not clear what CNS concentrations are necessary or sucient for neurobiological response.
We chose this timing with reference to the PRC to melatonin Lewy et al., 1998) . Here it is argued that exogenous melatonin should overlap the endogenous oset to optimize the magnitude of phase delays. It may also be argued that melatonin levels were still high around noon, which is approximately the time of the crossover from delays to advances Lewy et al., 1998) . Thus, by overlapping into the phaseadvance region in the afternoon, any delay initially induced would have been cancelled out. The same argument should also apply for evening administration of 5 mg of melatonin; here a phase advance is measurable in spite of overlapping into the putative phase-delay region at the end of the night. There is an alternative suggestion, that later timing, after endogenous melatonin had declined, might be more ecacious (as in Zaidan et al., 1994) .
In blind persons, sleep onset that is delayed or freerunning can be synchronized by advances after daily melatonin intake, yet rarely is the circadian system itself entrained Sack and Lewy, 1997) . Recently, a number of free-running blind subjects have been able to entrain with melatonin given after prior determination of their circadian phase position (Lockley et al., 2000; Sack et al., 2000) . It may be that high doses (10 mg) may even be initially necessary for such entrainment, although lower doses may subsequently maintain stable phase-position (Sack et al., 2000) . In such circadian pathologies, precise timing of application of melatonin is probably crucial. Further controlled studies are required to establish unequivocally whether daily doses of melatonin (for one, three, or more days) can elicit phase delays. Fig. 3 . Eect of melatonin on the three phase markers calculated on day 2 (n 9). The mid-range crossing times (MRCT) of core body temperature (CBT) and heart rate (HR) increase and dim light melatonin oset (DLMO) were measured in the morning; the MRCT of CBT and HR decline and dim light melatonin onset (DLMOn) were measured in the evening. As the threshold of 3 pg/mL for DLMOn was not reached by the last time-point at 23:00 hr in two subjects (one at baseline, one after melatonin administration), the average DLMOn is presented for n 7. When a 3-pg/mL value was interpolated at 23:30 hr in order to calculate for n 9, the results were similar. All subjects had clear DLMO values in the morning. The only signi®cant eect was an increased duration of higher-than-average CBT after melatonin (melatonin: 16:13 0.44 hr versus placebo: 15:14 0.53 hr; ANOVA, interaction: morning/evening versus plac/mel, P < 0.025).
